Barclays’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-34,406
| Closed | -$611K | – | 7671 |
|
|
2018
Q3 | $611K | Buy |
34,406
+29,593
| +615% | +$508K | ﹤0.01% | 4096 |
|
|
2018
Q2 | $66K | Sell |
4,813
-62,830
| -93% | -$746K | ﹤0.01% | 5497 |
|
|
2018
Q1 | $614K | Sell |
67,643
-35,466
| -34% | -$196K | ﹤0.01% | 3747 |
|
|
2017
Q4 | $441K | Buy |
103,109
+103,078
| +332,510% | +$491K | ﹤0.01% | 3984 |
|
|
2017
Q3 | $0 | Sell |
31
-42,177
| -100% | -$58.8K | ﹤0.01% | 7204 |
|
|
2017
Q2 | $63K | Buy |
42,208
+26,502
| +169% | +$56.9K | ﹤0.01% | 5225 |
|
|
2017
Q1 | $40K | Buy |
15,706
+7,232
| +85% | +$16.7K | ﹤0.01% | 5466 |
|
|
2016
Q4 | $21K | Buy |
8,474
+8,236
| +3,461% | +$23.6K | ﹤0.01% | 5612 |
|
|
2016
Q3 | $1K | Sell |
238
-286
| -55% | -$891 | ﹤0.01% | 6526 |
|
|
2016
Q2 | $2K | Buy |
524
+300
| +134% | +$1.1K | ﹤0.01% | 6020 |
|
|
2016
Q1 | $1K | Sell |
224
-361
| -62% | -$1.18K | ﹤0.01% | 6058 |
|
|
2015
Q4 | $2K | Sell |
585
-28,449
| -98% | -$131K | ﹤0.01% | 5782 |
|
|
2015
Q3 | $116K | Buy |
29,034
+15,531
| +115% | +$81.3K | ﹤0.01% | 4523 |
|
|
2015
Q2 | $68K | Sell |
13,503
-3,937
| -23% | -$23.6K | ﹤0.01% | 4961 |
|
|
2015
Q1 | $105K | Sell |
17,440
-620
| -3% | -$3.58K | ﹤0.01% | 4824 |
|
|
2014
Q4 | $110K | Buy |
18,060
+13,628
| +307% | +$83.1K | ﹤0.01% | 5132 |
|
|
2014
Q3 | $26K | Sell |
4,432
-5,845
| -57% | -$39.9K | ﹤0.01% | 6337 |
|
|
2014
Q2 | $63K | Sell |
10,277
-304,060
| -97% | -$3.42M | ﹤0.01% | 5783 |
|
|
2014
Q1 | $7.23M | Buy |
314,337
+312,642
| +18,445% | +$4.53M | 0.01% | 1411 |
|
|
2013
Q4 | $17K | Buy |
1,695
+304
| +22% | +$3.36K | ﹤0.01% | 6802 |
|
|
2013
Q3 | $18K | Sell |
1,391
-692
| -33% | -$10.9K | ﹤0.01% | 6568 |
|
|
2013
Q2 | $27K | Buy |
+2,083
| New | +$28.1K | ﹤0.01% | 6691 |
|
Other funds holding ECYT
Barclays's ECYT Position: Q4 2018 in Review
Barclays sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 34,406 shares — an estimated $611K sold.
Barclays first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $7.23M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Barclays reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Barclays sold 34,406 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $611K.
- Barclays first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
- Barclays's Endocyte, Inc. Common Stock position peaked at $7.23M in Q1 2014.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.